NovaBay Pharmaceuticals, Inc.
Health
Performance
8.2
Risk
Sell
Buy
Curious about the Scores? Learn more.

NovaBay Pharmaceuticals, Inc. stock rating and score history

All changes in ratings, performance and outlook tracked over time.

02.07.2026
Tiny rebound. Signs of life appear after deep struggle.
09.03.2026
Red alert. Risk levels out of control.
07.02.2026
Momentum tanked. Clearly underperforming.
NBY
NovaBay Pharmaceuticals, Inc.
1.47
-24.62%
8.2
Sell
Buy
NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals, Inc. stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does NovaBay Pharmaceuticals, Inc. do? Business model and key facts

Get the full picture of NovaBay Pharmaceuticals, Inc.: what it builds, where it operates, and how it makes money.

NovaBay Pharmaceuticals, Inc. Profile

Sector: Healthcare

Industry: Biotechnology

Employees (FY): 13

NovaBay Pharmaceuticals, Inc. (NBY) is a pharmaceutical company that specializes in developing and globally distributing products for eyecare and dermatology. Its product portfolio includes Avenova, an advanced solution designed for cleaning the delicate skin around the eye, such as the eyelids, by removing foreign substances, microorganisms, and debris. The company also offers wound management solutions under its NeutroPhase and PhaseOne brands. Furthermore, NovaBay provides a variety of dermatological treatments through its DERMAdoctor brand, addressing diverse skin concerns. These include conditions like keratosis pilaris, rosacea, and eczema, as well as anti-aging formulations, SPF protection, remedies for hyperhidrosis (excessive sweating), solutions for unwanted hair, and acne treatments. The company distributes its products through a multi-channel approach, utilizing traditional retailers, digital beauty platforms, various distributors, and its own online sales channels. Founded in 2000, the company was initially known as NovaCal Pharmaceuticals, Inc., before officially adopting the name NovaBay Pharmaceuticals, Inc. in February 2007. Its corporate headquarters are located in Emeryville, California.

shop
Company facts
Michael Kazley
CEO
13
Employees worldwide
shop
Performance
-48.42%
Last 12 months
-99.97%
Last 5 years
shop
Growth
$0
Revenue year
$-22,141,000
Net income
shop
Valuation
$39.14M
Market Cap
-0.01
Price/Earnings Ratio

Stocks related to NovaBay Pharmaceuticals, Inc.

Selected based on industry alignment and relative market positioning.

GOSS
Gossamer Bio, Inc.
0.14
-8.27%
10.0
Sell
Buy
Gossamer Bio, Inc.
TNYA
Tenaya Therapeutics, Inc.
0.80
-3.23%
9.2
Sell
Buy
Tenaya Therapeutics, Inc.
ARCT
Arcturus Therapeutics Holdings Inc.
5.90
-1.54%
9.1
Sell
Buy
Arcturus Therapeutics Holdings Inc.

Events and news impacting NovaBay Pharmaceuticals, Inc. stock

Earnings, coporate decisions and industry developments that can affect the share price.

NovaBay Pharmaceuticals, Inc. fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.